Find Clinical Trials

On this page, you will find different kinds of study results:

• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.

219 Results

Protocol Code	Study Title	Active substance/Medical device	Study Phase	Therapeutic Area
CL2-95005-002	An open-label, randomised, non-comparative phase 2 study evaluating S 95005 (TAS-102) plus bevacizumab and capecitabine…	TIPIRACIL, TRIFLURIDINE, S095005	Phase 2	Cancers
CL2-90652-002	Safety and effects on blood pressure of a daily dose of 0.025 to 0.135 milligram…	PERINDOPRIL ARGININE, S090652	Phase 2	Cardiovascular Diseases
CL2-90652-001	Acceptability, safety, pharmacokinetics and effects on blood pressure of a daily dose of 0.025 to…	PERINDOPRIL ARGININE, S090652	Phase 2	Cardiovascular Diseases
CL2-90098-009	Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over…	AGOMELATINE, S090098	Phase 2	Neuropsychiatric Diseases
CL2-90098-005	Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for…	AGOMELATINE, S090098	Phase 2	Neuropsychiatric Diseases
CL2-80881-001	An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified…	LUCITANIB, S080881	Phase 2	Cancers
CL2-78989-018	An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in…	GEVOKIZUMAB, S078989	Phase 2	Immune-Inflammatory Diseases
CL2-78989-012	A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in…	GEVOKIZUMAB, S078989	Phase 2	Immune-Inflammatory Diseases
CL2-78989-011	Dose-response study of gevokizumab (S78989) 3mg, 10mg, 30mg or 60mg in patients with type 2…	GEVOKIZUMAB, S078989	Phase 2	Metabolism
CL2-78989-010	A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every…	GEVOKIZUMAB, S078989	Phase 2	Immune-Inflammatory Diseases
CL2-78989-009	Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation…	GEVOKIZUMAB, S078989	Phase 2	Cardiovascular Diseases
CL2-78989-001	An open-label safety and pharmacokinetic study of gevokizumab in subjects with Behçet's disease uveitis	GEVOKIZUMAB, S078989	Phase 2	Other
CL2-47445-014	Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major Depressive Disorder…	S047445	Phase 2	Neuropsychiatric Diseases
CL2-47445-011	Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer's…	S047445	Phase 2	Neuropsychiatric Diseases
CL2-44819-004	Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event. International,…	S044819	Phase 2	Neuropsychiatric Diseases
CL2-44497-004	Dose ranging study of S 44497 administered orally once daily for four weeks in type…	S044497	Phase 2	Metabolism
CL2-44121-008	Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia…	S044121	Phase 2	Cardiovascular Diseases
CL2-44121-006	Evaluation of the anti-arrhythmic effects of 3 oral dosages of S 44121 versus placebo in…	S044121	Phase 2	Cardiovascular Diseases
CL2-44121-005	Effects of three oral dosages of S 44121 on cardiac arrhythmia during exercise testing in…	S044121	Phase 2	Cardiovascular Diseases
CL2-44121-004	Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac…	S044121	Phase 2	Cardiovascular Diseases
CL2-44121-003	Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac…	S044121	Phase 2	Cardiovascular Diseases
CL2-38844-010	Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844…	S038844	Phase 2	Cardiovascular Diseases
CL2-38093-012	Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus…	S038093	Phase 2	Neuropsychiatric Diseases
CL2-38093-011	Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus…	S038093	Phase 2	Neuropsychiatric Diseases
CL2-38093-009	Safety and efficacy of S 38093 and donepezil, during 4 weeks, in patients with mild…	S038093	Phase 2	Neuropsychiatric Diseases

Previous 1 2 … 6 7 8 9 Next